Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as a therapy based on animal models of the disease and our prior clinical research to observe any objective improvement in the extent of the disease using Magnetic Resonance Imaging (MRI)and standard measurements for other gynecologic diseases to measure symptomatology.

All patients will get a baseline imaging of the uterus with MRI and a brief procedure, similar to a pap smear, to obtain tissue from the uterus and also a blood draw. Patients will then receive vaginal bromocriptine twice daily and will be reassessed at 6 months with an MRI to see objective improvement in the extent of the disease. This 6 month visit is the only one that would require an in person visit to the research site (Mayo Clinic in this case)

Secondary Outcome Measures:

Scores from questionnaires that assess the severity of symptoms from adenomyosis [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Patients will fill out questionnaires at 1, 3, 6 and 9 months. These questionnaires are validated for study of gynecologic diseases and assess the severity of symptoms in patients.

Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.

Drug: Vaginal Bromocriptine

Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.

Other Names:

Cycloset

Parlodel

Detailed Description:

Women with adenomyosis proven with MRI will be considered for the intervention with bromocriptine. They will be reassessed at 1, 6 and 9 months. Patients will get a stipend for each visit they complete. The study will end for the enrolled subject at 9th month follow-up

Eligibility

Ages Eligible for Study:

25 Years to 55 Years (Adult)

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Women able to give informed consent and willing and able to attend all study visits

Premenopausal women at least 25 years of age

No evidence of High Grade SIL by pap smears or HPV testing within institutional guidelines

MRI or ultrasound imaging consistent or highly suggestive of adenomyosis

Use of barrier contraception, sterilization or sexual abstinence

Exclusion Criteria:

Women actively trying for pregnancy, currently pregnant, less than six months postpartum or breastfeeding

Uterine size > 20 weeks

Active pelvic infection or current use of intrauterine contraceptive device

Current use of GnRH agonists or antagonists, or contraceptive steroids

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01821001